Sandoz Group (OTCMKTS:SDZNY) Cut to Hold at Barclays

Barclays downgraded shares of Sandoz Group (OTCMKTS:SDZNY) from a strong-buy rating to a hold rating in a research report released on Thursday morning,Zacks.com reports.

Separately, Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Sandoz Group has a consensus rating of “Buy”.

Sandoz Group Price Performance

Shares of OTCMKTS SDZNY opened at $88.02 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62. Sandoz Group has a 12 month low of $35.61 and a 12 month high of $94.15. The business has a fifty day simple moving average of $79.44 and a 200-day simple moving average of $69.60.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.